These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 7712662)

  • 1. Pharmacokinetic optimisation of the treatment of embolic disorders.
    Lutomski DM; Bottorff M; Sangha K
    Clin Pharmacokinet; 1995 Jan; 28(1):67-92. PubMed ID: 7712662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of antithrombotic drugs in older people.
    Tufano A; Cerbone AM; Di Minno G
    Minerva Med; 2002 Feb; 93(1):13-26. PubMed ID: 11850611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic drugs for older subjects. Guidelines formulated jointly by the Italian Societies of Haemostasis and Thrombosis (SISET) and of Gerontology and Geriatrics (SIGG).
    Di Minno G; Tufano A; Cerbone AM
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):41-62. PubMed ID: 11383324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of LMWHs.
    Samama MM; Gerotziafas GT
    Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Dunn CJ; Sorkin EM
    Drugs; 1996 Aug; 52(2):276-305. PubMed ID: 8841743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytics: drug interactions of clinical significance.
    Harder S; Klinkhardt U
    Drug Saf; 2000 Nov; 23(5):391-9. PubMed ID: 11085346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
    Cheer SM; Dunn CJ; Foster R
    Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.
    Davis R; Faulds D
    Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heparins].
    Marbet GA
    Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations.
    Harder S; Klinkhardt U; Alvarez JM
    Clin Pharmacokinet; 2004; 43(14):963-81. PubMed ID: 15530128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.
    Chapman TM; Goa KL
    Drugs; 2003; 63(21):2357-77. PubMed ID: 14524738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of arterial and venous brain ischemia. Experts' recommendations: stroke management in the intensive care unit].
    Calvet D; Bracard S; Mas JL;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):512-21. PubMed ID: 22647807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G; Marino P
    Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.